AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer

Código QR

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer

BackgroundAlthough immunotherapy has been used in the treatment of metastatic triple negative breast cancer (TNBC), its therapeutic influence on human epidermal growth factor receptor 2 (HER2)-positive subtype remains controversial. It is therefore imperative to find biomarkers that can predict the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Long Wang, Xue Zhang, Mengxue Wang, Yunhai Li, Jiali Xu, Jiaying Wei, Hongzhong Li, Guosheng Ren, Xuedong Yin
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	HER2-positive breast cancer AMPD1 tumor microenvironment tumor-infiltrating immune cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b1b49b8e9b304d6ebdae4cb24b502b3a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
por: Cor J. Ravensbergen, et al.
Publicado: (2021)

A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy
por: Chenyu Mao, et al.
Publicado: (2021)

Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients
por: Gedmante Radziuviene, et al.
Publicado: (2021)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub NM, et al.
Publicado: (2019)

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Ilana Schlam, et al.
Publicado: (2021)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021)

Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer
por: Jianyu Liu, et al.
Publicado: (2021)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Yunhai Li, et al.
Publicado: (2021)

Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies
por: Hua Zhao, et al.
Publicado: (2021)

Identification of a Six-Gene Prognostic Signature Characterized by Tumor Microenvironment Immune Profiles in Clear Cell Renal Cell Carcinoma
por: Lu Zhang, et al.
Publicado: (2021)

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
por: Jiao Hu, et al.
Publicado: (2021)

Immune Infiltration, Cancer Stemness, and Targeted Therapy in Gastrointestinal Stromal Tumor
por: Jingjing Wang, et al.
Publicado: (2021)

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Amy J. Petty, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jesse Lopes da Silva, et al.
Publicado: (2021)

Nanotechnology-enhanced immunotherapy for metastatic cancer
por: Peisen Zhang, et al.
Publicado: (2021)

Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
por: Guangdi Chu, et al.
Publicado: (2021)

A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study
por: Yizhou Huang, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy
por: Siyuan Chen, et al.
Publicado: (2021)

Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma
por: Lu Zhang, et al.
Publicado: (2021)

PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration
por: Liu X, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower EE, et al.
Publicado: (2017)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway
por: Peipei Yang, et al.
Publicado: (2021)

Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
por: Madison Pereira, et al.
Publicado: (2021)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Chao Li, et al.
Publicado: (2021)

Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
por: Changbo Sun, et al.
Publicado: (2021)

The identification of tumor-infiltrating lymphocytes in patients with stomach cancer
por: Gulnoz G. Khakimova, et al.
Publicado: (2021)

The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
por: Dmitrii V. Tabakov, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Xiangdong Ye, et al.
Publicado: (2021)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Matteo Allegretti, et al.
Publicado: (2021)

Down-Regulation of USP8 Suppresses HER-3 Positive Gastric Cancer Cells Proliferation [Corrigendum]
por: Sun J, et al.
Publicado: (2021)

Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma
por: Min Yan, et al.
Publicado: (2021)

Exposure to Tobacco Smoking Induces a subset of Activated Tumor-resident Tregs in Non-Small Cell Lung Cancer
por: Yudi Hu, et al.
Publicado: (2022)

Prognostic Impact of Tumor-Associated Macrophages on Long-Term Oncologic Outcomes in Colorectal Cancer
por: Hyeong Chan Shin, et al.
Publicado: (2021)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
por: Serafin Morales, et al.
Publicado: (2021)

COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
por: Sujie Gu, et al.
Publicado: (2021)

Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients’ bone marrow
por: Huynh Cao, et al.
Publicado: (2021)

Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
por: Hae Woong Choi, et al.
Publicado: (2021)